Cc-99677, a novel, oral, selective covalent mk2 inhibitor, sustainably reduces pro-inflammatory cytokine production

HIGHLIGHTS

• who: Rajula Gaur from the Bristol Myers Squibb, Princeton, NJ, USA have published the article: CC-99677, a novel, oral, selective covalent MK2 inhibitor, sustainably reduces pro-inflammatory cytokine production, in the Journal: (JOURNAL)
• what: A novel in vitro model was developed to compare the potential for tachyphylaxis of CC-99677 and p38 inhibitors in THP-1 cells. Actinomycin D treatment in the study demonstrated that CC-99677-mediated inhibition of TTP phosphorylation results in increased decay of cytokine mRNAs.
• future: Future studies will explore the effect of CC-99677 on TTP-mediated . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.